This paper was presented in abstract form via poster presentation at the 2013 ACVIM Forum, Seattle, WA
Acute Effects of Ivabradine on Dynamic Obstruction of the Left Ventricular Outflow Tract in Cats with Preclinical Hypertrophic Cardiomyopathy
Version of Record online: 5 MAR 2014
Copyright © 2014 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 28, Issue 3, pages 838–846, May/June 2014
How to Cite
Blass, K.A., Schober, K.E., Li, X., Scansen, B.A. and Bonagura, J.D. (2014), Acute Effects of Ivabradine on Dynamic Obstruction of the Left Ventricular Outflow Tract in Cats with Preclinical Hypertrophic Cardiomyopathy. Journal of Veterinary Internal Medicine, 28: 838–846. doi: 10.1111/jvim.12331
- Issue online: 28 APR 2014
- Version of Record online: 5 MAR 2014
- Manuscript Accepted: 20 JAN 2014
- Manuscript Revised: 27 NOV 2013
- Manuscript Received: 19 AUG 2013
- The Ohio State University
- If current;
- Systolic anterior motion
Ivabradine is a negative chronotropic drug with minimal effects on central hemodynamics. Its effect on dynamic obstruction of the left ventricular outflow tract (LVOT) in cats with hypertrophic cardiomyopathy (HCM) remains unknown.
Ivabradine reduces dynamic obstruction of the LVOT in cats with HCM.
Twenty-eight client-owned cats with preclinical HCM and dynamic LVOT obstruction.
Randomized, double-blind, active-control single dose study. Cats received a single dose of either ivabradine (0.3 mg/kg PO) or atenolol (2 mg/kg PO). Heart rate, echocardiographic variables, and systolic blood pressure (SBP) were recorded before and 3 hours after drug administration. Statistical comparisons were made using ANCOVA.
Peak velocity in the LVOT was significantly decreased compared to baseline for both drugs; however, the effect was more prominent with atenolol (mean reduction 2.53 m/s; 95% CI 2.07–3.13 m/s) compared to ivabradine (mean reduction 0.32 m/s; 95% CI −0.04 to 0.71 m/s; P < .0001). Echocardiographic indices of systolic function were largely unchanged by ivabradine, but significantly reduced by atenolol.
Conclusions and Clinical Importance
A single dose of ivabradine decreases dynamic LVOT obstruction in cats with HCM, but the clinical effect is negligible and inferior compared to that achieved by atenolol.